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Oncogenic osteomalacia is a rare paraneoplastic syndrome characterized by severe
hypophosphoremia due to renal phosphate wasting and osteomalacia clinically near to hereditary
hypophosphoremic rickets. This disorder is induced by a benign tumor which belongs to the group
of « phosphaturic mesenchymal tumor mixed connective tissue variant » secreting phosphaturic
factors. We report the case of a 54-year old man who presented with diffuse bone pain and bilateral
hip pain evolving for 3 years. Physical examination revealed a subcutaneous tumor of the left
flank. A radiographic skeletal survey showed signs of osteomalacia with an overall « washed-out »
appearance of the bone, cuneiform aspect of dorsolombar vertebral bodies and bilateral fracture of
femoral necks. Serum Fibroblast Growth Factor 23 concentration was high. The patient had total
bilateral hips arthroplasty and surgical removal of the tumor of the flank was performed. There
was rapid improvement and the laboratory values returned to normal.
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Introduction
Oncogenic osteomalacia (OO) is a rare paraneoplastic syndrome characterized by severe
hypophosphoremia due to renal phosphate wasting and osteomalacia clinically near to hereditary
hypophosphoremic rickets. This disorder is induced by a benign tumor which belongs to the group of
« phosphaturic mesenchymal tumor mixed connective tissue variant » (PMTMC) (1), secreting
phosphaturic factors. Despite its frequent association wih OO, PMTMC commonly presents clinical
difficulties both in diagnosis and management.  Measurement of Fibroblast Growth Factor 23 (FGF-
23), a new identified clinical marker for oncogenic osteomalacia, has been recently of considerable
importance for early diagnosis of this disorder.
We report here in a new case of oncogenic osteomalacia linked to a mesenchymal tumor of the flank
compatible with the features of PMTMC.
Case Report
A 54-year old man, with no medical history, presented with diffuse bone pain and bilateral hip pain
evolving for 3 years, having insidiously caused functional disability. The patient has been confined
for a year because of permanent asthenia, weight loss. Physical examination revealed a painless
mobile 3-centimeter diameter subcutaneous tumor of the left flank, primarily evoking lipoma. The
patient was admitted for detailed investigations. Biology revealed low levels for serum inorganic
phosphorus (0.52 mM; N: 0.85-1.45 mM), hyperphosphaturia (72 Mm / 24h; N: 12-40 Mm) and
hypocalciuria (1.70 mM; N: 2.25-2.62 mM). A low level for serum 1,25-(OH) vitamin D (7 pM; N:
16-56 pM) was found, whereas serum levels of ionized calcium and 25(OH) vitamin D were normal.
Serum and bone alkaline phosphatase were elevated (respectively 352 U/L; N: 38-115 and 87.1
ng/mL; N: 7.5-16), as well as serum intact PTH (95ng/mL; VN: 3-51 ng/mL).  A radiographic skeletal
survey showed signs of osteomalacia with an overall « washed-out » appearance of the bone,
cuneiform aspect of dorsolumbar vertebral bodies and bilateral fracture of femoral necks Garden 4
(Figure1).
Diagnosis of hyperparathyroidism was first made but rapidly excluded since cervical ultrasonography
didn’t show parathyroid adenoma. Hypothesis of oncogenic osteomalacia was therefore evoked.
Serum FGF-23 concentration was subsequently evaluated and was high estimated to 88 pg/mL (N <
40 pg/mL) confirming the suspected diagnosis.
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Figure1: Bilateral femoral necks fractures
Figure 2. Total bilateral hip arthroplasty
According to this, the patient had total bilateral hips arthroplasty 2 weeks a part (Figure 2) and
surgical removal of the tumor of the flank was performed. Histological examination revealed an
encapsulated tumor made of double adipic and vascular components including some
hypervascularized areas and a well-defined central area with swelling, necrotic and haemorragic
changes. There were neither mitoses nor tumoral necrosis favourable to malignancy. These
histopathological features were compatible with the diagnosis of angiolipoma.
After surgery, the patient had multivitamin supplementation and intensive reeducation program.
Outcome was favorable with correction of hypophosphatemia within 15 days following surgery.
Clinically, he was able to walk using crutches and his pain improved.
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Discussion
We reported here an anatomoclinical case of oncogenic osteomalacia in an old man due to a small,
histologically benign tumor secreting high levels of FGF-23. In our patient, clinical features were
typical with weakness, bone pain and spontaneous fractures. Biochemical abnormalities were also
suggestive of oncogenic osteomalacia, namely hypophosphatemia and decreased serum 1-25-(OH)2
vitamin D3 levels.
Since the first description of oncogenic osteomalacia by Prader1 in 1959, few cases have been
reported in the literature2. Diagnosis is often made in adult patients over 30 years 3 as it is the case of
our patient. This condition is problematic to recognise making the delay for diagnosis usually long
ranging from few months to 19 years with an average delay of 2.5 years 3, 4.  Infact, the causative
tumor may be small (varying from 1 to 15 cm), slow growing, and clinically unapparent. Moreover,
these tumors may occur in many different locations, often making their detection difficult. Many
histological types of these tumors have been reported 2, 5 such as haemangiopericytoma, giant cell
tumor, osteoblastoma or angiolipoma such the case of our patient. Anyway, these tumors, usually
benign, may also be malignant 2, 6. Actually, cases of osteosarcoma, colon adenocarcinoma, breast or
prostatic cancer have been described in association with oncogenic osteomalacia 1, 4, 7, 8, 9. Implicated
tumors are usually located on the head and neck, preferentially in sinus and mandible. As in our
patient, they also mainly affect bone and soft tissue 3,7-11,15,16 especially in the lower extremities 17.
They are histologically characterized by admixture of mesenchymatous cells and conjunctival tissue.
Four histopathological contingents are suggestive for the diagnosis: spindle cells, osteoclast-like giant
cells, cartilage-like matrix or metaplastic bone and haemangipericytoma-like vascularization. Authors
recognized that many of these tumors are quite distinctive but it was not until the study of Weidner
and Santa Cruz14 that the term « phosphaturic mesenchymal tumor mixed connective tissue variant »
was proposed to describe these particular lesions, a notion that was later emphazized by Folpe et al 1.
PMTMCT and other uncommon tumors causative of osteomalacia syndrome markedly over-express
factors, causing impaired phosphocalcic and vitamin D metabolism18. Hypophosphatemia is due to
excessive renal phosphate wasting induced by this new class of phosphaturic factors called
phosphatonins; among them FGF-23 is considered as the new clinical marker for OO. Its action
consists of inhibition of renal phosphate uptake and of 1-25 (OH) Vitamin D synthesis from 25 (OH)
Vitamin D by inhibiting 1 alpha hydroxylase. That’s why, we notice decreased serum levels of 1-25
(OH) Vitamin D even with hypophosphatemia 19.
As previously reported 20, 21, FGF-23 level was determined in our case by ELISA. In oncogenic
osteomalacia, if the causative tumor can be located and completely removed, there is a rapid
normalization of serum phosphate and remission of the disease. This evolution suggests that FGF-23
play a key role in this disease. In our patient, surgical removal of the flank tumor relieved symptoms
with biochemical normalization within 15 days after surgery. However, after effects were noticed in
our patient because of the delay of diagnosis. This to focus on the importance of early diagnosis of
oncogenic osteomalacia to avoid sequelae.
Because surgical removal of the responsible tumor is the only satisfactory treatment, identification of
the tumors is clinically essential. In our patient, diagnosis was quite easy since he had a clinically
apparent tumor and typical biochemical features of oncogenic osteomalacia. Otherwise, diagnosis is
usually hard in patients where tumor is difficult to locate and slow-growing. Recently, the use of
PET/SCAN made it easier. However, FGF-23 measurement remains of considerable importance for
facilitating early diagnosis of oncogenic osteomalacia, even if it is not specific of this condition since
high levels are also found in X linked hypophosphatemia and autosomal dominant hypophosphatemic
rickets. In the latter, the ground of pediatric patients with positive family history is suggestive.
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Conclusion
We reported here a typical case of OO, a rare clinicipathologic entity linked to a mesenchymal tumor
which overexpresses a hypophosphatemic factor, FGF-23, causing the major symptoms of the disease.
Our patient experienced rapid remission after excision of the causative tumor. This is to highlight the
importance of considering OO in the differential diagnosis of osteomalacia syndrome to avoid a
delayed diagnosis and then sequelae.
References
1. Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, et al. Most
osteomalacia-associated mesenchymal tumors are a single histopathologic entity. An analysis
of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 2004; 28: 1-30.
2. Dupond JL, Magy N, Mahammedi M, Prie D, Gil H, Meaux-Ruault N, Kantelip B. Oncogenic
osteomalacia: the role of the phosphatonins. Diagnostic usefulness of the Fibroblast Growth
Factor 23 measurement in one patient. La revue de la médecine interne 2005; 26: 238-41.
3. Casari J, Rossi V, Varenna M, Gasparini M, Parafioriti A, Failoni A, et al. A case of oncogenic
osteomalacia detected by 111 IN-pentet-reotide total body scan. Clin Exp Rheumatol 2003; 21:
493-6.
4. Charpenter TO. Oncogenic Osteomalacia. A complex dance of factors. New Engl J Med 2003;
348: 1705-8.
5. Cho SI, Do NY, Yu SW, Choi JY. Nasal hemangiopericytoma causing oncogenic
osteomalacia. Clin Exp Otorhinolaryngol 2012; 5: 173-6.
6. Chiam P, Tan HC, Bee YM, Chandran M. Oncogenic osteomalacia-hypophosphataemic
spectrum from “benignancy” to “malignancy”. Bone 2013; 53: 182-7.
7. Park YK, Unni KK, Beabout JW, Hodgson JF. Oncogenic Osteomalacia. A clinicopathological
study of 17 bone lesions. J Korean Med Sci 1994; 9: 289-98.
8. Drezner MK. Tumor-induced osteomalacia. In: Favus MJ, editor. Primer on the metabolic
bone diseases and disorders of mineral metabolism. 4th ed. Philadelphia: Lippicott William
and Wilkins; 1999.p. 33-7.
9. Leaf DE, Pereira RC, Bazari H, Juppner H. Oncogenic osteomalacia due to FGF 23 expressing
colon adenocarcinoma. J Clin Endocrinol Metab 2013 Feb 7 [Epub ahead of print].
10. Nguyen BD, Wang EA. Indium-pentetreotide scintigraphy of mesenchymal tumor with
oncogenic osteomalacia. Clin Nucl Med 1999; 24: 130-1.
11. Beyer T, Antoch G, Muller S, Egelhof T, Freudenberg LS, Debatin J, et al. Acquisition
protocol considerations for combined PET/CT imaging. J Nucl Med 2004; 45 (suppl 1): 25S-
35S.
12. Koeger AC, Prier A, Vinceneux PH, Camus JP. Les ostéomalacies tumorales
hypophosphorémiques. Press Med 1985; 14: 1747-51.
13. Weiss D, Bar RS, Weidner N, Wener M, Lee F. Oncogenic osteomalacia: strange tumor in
strange places. Post-Graduate Med J 1985; 61: 349-55.
14. Weidner N, Santa Cruz D. Phosphaturic mesenchymal tumors: a polymorphous group
causing osteomalacia or rickets. Cancer 1987; 59: 1442-54.
15. Mathis DA, Stehel EJ Jr, Beshay JE, Mickey BE, Folpe AL, Raisanen J. Intracranial
phosphaturic mesenchymal tumors. J Neurosurg 2013 Jan 25 [Epub ahead of print].
16. Niemeier T, Leddy L, Bolster M, Chapin R. Insufficiency fracture associated with oncogenic
osteomalacia. J Clin Rheumatol 2013; 19: 38-42.
17. Jiang Y, Xia WB, Xing XP, et al. Tumor-induced osteomalacia : an important cause of adult
onset hypophosphatemic osteomalacia in China : report of 39 cases and review of the
literature. J Bone Miner Res 2012; 27: 1967-75.
18. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T,
Fukumoto S, Yamashita T. Cloning and characterization of FGF-23 as a causative factor of
tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001; 98: 6500-5.
ISSN 2073-9990   East Cent. Afr. J. surg
179 COSECSA/ASEA Publication -East and Central African Journal of Surgery.  July/August; 2013 Volume 18 (2)
19. Nelson AE, Clifton Bligh R, Mirams M, Gill A, AU A, Clarkson A, Juppner H, Ruff S, et al.
Fibroblast Growth Factor 23: A new clinical marker for oncogenic osteomalacia. J Clin
Endocrinol Metab 2003; 88: 4088-94.
20. Harlow E, and Lane D 1988 Two antibody sandwich assays. In: antibodies: A laboratory
Manual. New York : Cold Spring Harbor Laboratory ; 479-81.
21. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, et al. Increased
circulatory level of biologically active full-length FGF-23 in patients with hypophosphoremic
rickets/osteomalacia. J Clin Endocrinol Metab 2002 ; 87 : 4957-4960.
